Local view for "http://purl.org/linkedpolitics/eu/plenary/2009-01-13-Speech-2-383"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20090113.29.2-383"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Madam President, Commissioner Verheugen, as you said, this package was much talked about even before it was tabled. This is perhaps not particularly strange, as pharmaceutical products affect everyone. However, they also affect powerful companies with strong interests as well as the use of tax revenue.
I, personally, asked the Commission to include the effect of pharmaceutical products on the environment in the information provided. I am very pleased that the Commission has included this in its proposal as something that may be included in the information that may be provided. However, I think, in fact, that this information probably could be mandatory when providing information about the pharmaceutical product.
I do not want to see advertisements for prescription pharmaceutical products. I am therefore pleased that the Commission appears to share this view. However, like the Commission, I believe that patients and the general public should have the right to sound and accurate information on pharmaceutical products. In several cases this already exists today. In Sweden, for example, we have a system called FASS. It is important for it to be possible, as an ordinary citizen, to find reliable information quickly, particularly in view of the fact that there is plenty of information that is downright misleading, in particular in various chat rooms on the Internet that are easy to find if someone is in a vulnerable situation. However, just as the Commission has proposed, it is necessary for the information to be monitored objectively so that it can be relied upon. It is this part of the Commission’s proposal that I am quite dubious about. It will be extremely important to regulate how these information channels can and should be set up, so that they are easily accessible while at the same time only accessible to those looking for the information, so that the information is not given to people who have not asked for it like an advertisement.
I am also a little dubious about whether it is really necessary to have full regulation of this matter at EU level. When all is said and done, this is an area that relates to health services and medical care and that should fall mostly within the competence of the Member States. I would therefore prefer to be a little more convinced that the legislative regulation of this matter at EU level was really necessary."@en1
|
lpv:videoURI |
Named graphs describing this resource:
The resource appears as object in 2 triples